Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough

SIMPLE SUMMARY: The treatment scenario of metastatic renal cell carcinoma has drastically changed in recent years, with the advent of immunotherapy. Since 2015 immune-checkpoint inhibitors, either alone or in combination with other compounds, are constantly enriching the treatment scenario, with a d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Mollica, Veronica, Brocchi, Stefano, Dall’Olio, Filippo Gustavo, Marcolin, Laura, Paccapelo, Alexandro, Santoni, Matteo, Rizzo, Alessandro, Montironi, Rodolfo, Golfieri, Rita, Massari, Francesco, Ardizzoni, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8304626/
https://ncbi.nlm.nih.gov/pubmed/34298702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13143492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados